Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm |
Domain |
PF03129 Anticodon binding domain PF02824 TGS domain PF00587 tRNA synthetase class II core domain (G PF07973 Threonyl and Alanyl tRNA synthetase second additional domain |
Function |
- |
Biological Process |
GO:0006399 tRNA metabolic process GO:0006418 tRNA aminoacylation for protein translation GO:0006435 threonyl-tRNA aminoacylation GO:0006520 cellular amino acid metabolic process GO:0043038 amino acid activation GO:0043039 tRNA aminoacylation |
Molecular Function |
GO:0004812 aminoacyl-tRNA ligase activity GO:0004829 threonine-tRNA ligase activity GO:0016874 ligase activity GO:0016875 ligase activity, forming carbon-oxygen bonds GO:0016876 ligase activity, forming aminoacyl-tRNA and related compounds |
Cellular Component | - |
KEGG |
hsa00970 Aminoacyl-tRNA biosynthesis |
Reactome | - |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TARSL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TARSL2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TARSL2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of TARSL2 in various data sets.
|
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TARSL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TARSL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TARSL2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TARSL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TARSL2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TARSL2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | TARSL2 |
Name | threonyl-tRNA synthetase-like 2 |
Aliases | FLJ25005; probable threonyl-tRNA synthetase 2, cytoplasmic; threonine--tRNA ligase; threonyl-tRNA synthetase ...... |
Chromosomal Location | 15q26.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting TARSL2 collected from DrugBank database. |
There is no record. |